Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 15/20 | 0.57 |
| ▸ | RARB | P10826 | 15/20 | 0.57 |
| ▸ | RARA | P10276 | 13/20 | 0.57 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.52 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 5/20 | 0.49 |
| ▸ | RXRB | P28702 | 2/20 | 0.49 |
| ▸ | RXRG | P48443 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048070 | 1.00 | RARG (0.57) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5045747 | 0.89 | RARB (0.54) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5045745 | 0.89 | RARB (0.54) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5046345 | 0.87 | RARG (0.66) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL9746403 | 0.82 | RARB (0.75) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5712126 | 0.82 | RARB (0.75) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5712098 | 0.82 | RARB (0.75) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL5048089 | 0.79 | RARG (0.69) | RARGRARBRARACYP26A1CYP26B1 | |
| SCHEMBL1406576 | 0.76 | RARG (0.45) | RARGRARBRARARXRARXRB | |
| SCHEMBL1406812 | 0.75 | RXRA (0.51) | RARGRARBRARACYP26A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | claimed |
| US-7468457-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | RARG 3/4885RARB 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.